What is the current price of a box of Tarlatamab?

Tarlatamab (Tarlatamab) is an innovative bispecific T cell-engaging drug developed by Amgen (Amgen) agent (BiTE), mainly used to treat patients with extensive-stage small cell lung cancer (ES-SCLC), especially for adult patients whose disease has progressed after platinum-based chemotherapy. This drug inhibits the development of cancer by activating the patient's own immune system to recognize and attack tumor cells. In 2024May month, talatumumab received accelerated approval from the U.S. FDA and became an important treatment option in this field.

In the U.S. market, talatumumab is relatively expensive. The cost of an initial treatment cycle is approximately $31,500 and each subsequent cycle is approximately $30,000, with the overall cost of treatment expected to exceed $160,000. Due to its high price, talatumumab has not yet been launched in mainland China, nor has it been included in the medical insurance catalog, making it difficult for domestic patients to purchase this drug through formal channels.

In China, talatumumab mainly exists in the form of scientific research reagents. Some biotechnology companies provide scientific research products with specifications of 1mg at a price of about 7,500 yuan. These products are for experimental research use only and are not suitable for clinical treatment. If patients need to use the drugs, they need to obtain the drugs through foreign medical services or go overseas for medical treatment. This not only involves higher costs, but may also face complex legal and logistical issues.

Overall, talatumumab, as a cutting-edge immunotherapy drug, shows positive prospects in the treatment of small cell lung cancer. Although the current availability in the Chinese market is relatively limited, with technological advancement and policy adjustments, it is expected to gradually enter the scope of domestic clinical use in the future, bringing new treatment hope to more patients. When considering use, patients should fully understand the relevant information and carefully choose appropriate channels and treatment options.

Reference materials:https://www.drugs.com/donanemab.html